Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cell Therapeutics adds three members to advisory board

This article was originally published in Scrip

Executive Summary

Biopharmaceutical company Cell Therapeutics has appointed Alan List, Ross Levine and Brian Druker to its recently formed scientific advisory board. All three newly named members have expertise in blood cancer research and development. Dr List is president and CEO of Moffitt Cancer Center and a professor of internal medicine and oncology at the University of South Florida College of Medicine; Dr Levine is associate attending physician at Memorial Sloan-Kettering Cancer Center; and Dr Druker is director of the Knight Cancer Institute at Oregon Health and Science University (OHSU), chair of Leukemia Research at OHSU, and an Investigator of the Howard Hughes Medical Institute. The advisory board will advise on the development of Cell's oncology programs and evaluate new opportunities in the treatment of blood-related cancers.

You may also be interested in...

A Backstage View Of Roche’s Recent Collaborations

In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.

Fact File: Coronavirus Medtech And Diagnostic Updates

As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.

Making Progress Against Rare Diseases

Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts